| BTX Stock | | | ILS 212.90 8.70 3.93% |
Lineage Cell market-risk-adjusted-performance technical analysis lookup allows you to check this and other technical indicators for Lineage Cell Therapeutics or any other equities. You can select from a set of available technical indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations and data normalization technicques. Please check also
Equity Screeners to view more equity screening tools
Lineage Cell Therapeutics has current Market Risk Adjusted Performance of 0.8646.
MRAP | = | ER[a] + (1/BETA - 1) | X | ER[a] - RFR) |
| = | 0.8646 | |
| ER[a] | = | Expected return on investing in Lineage Cell |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
| BETA | = | Beta of the asset with market or selected benchmark. |
Lineage Cell Market Risk Adjusted Performance Peers Comparison
Lineage Market Risk Adjusted Performance Relative To Other Indicators
Lineage Cell Therapeutics is rated
fourth in market risk adjusted performance category among its peers. It is currently under evaluation in maximum drawdown category among its peers reporting about
35.53 of Maximum Drawdown per Market Risk Adjusted Performance. The ratio of Maximum Drawdown to Market Risk Adjusted Performance for Lineage Cell Therapeutics is roughly
35.53
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.